Angelo Antonini
Angelo Antonini is an expert in Neurology at Azienda Ospedaliera di Padova (Italy). As of October 2026, ScienceLeadR ranks Angelo Antonini in the top 1% of experts worldwide for Parkinson Disease, Basal Ganglia Diseases and Cognition Disorders. Angelo Antonini has authored 861 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 5 of them ongoing. SLR score: 2,858 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Biochemistry - Psychiatry - Informatics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1993 - 2026
Number : 861
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Evidence-Based Reviews and Evidence-Based Guidelines: Understanding Apparent Discrepancies. PMID 42768712 — movement disorders | Mov Disord | 2026 | 0 |
| Correction to: Device aided therapies in Parkinson disease: an expert view on apomorphine. PMID 42754732 — parkinson disease, apomorphine, neurosciences, therapeutics | Neurol Sci | 2026 | 0 |
| Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape. PMID 42742463 — parkinson disease, therapeutics | J Parkinsons Dis | 2026 | 0 |
| Cerebellar and brainstem MRI alterations in primary brain calcification. PMID 42579136 — middle cerebellar peduncle, atrophy, brain, radiography, cerebellum, brain stem, cerebellar cortex | Neuroradiology | 2026 | 0 |
| Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial. PMID 42561742 — safety, parkinson disease, tremor, therapeutics, nervous system diseases, cytidine diphosphate choline | Parkinsonism Relat Disord | 2026 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3b open label randomised study of IPX203 in subjects with advanced Parkinson s disease and motor fluctuations ADIP study 2025-521772-57-00 — parkinson disease | Phase 3 | Active not recruiting | 2025 |
| A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson s Disease 2023-507132-21-00 — safety, parkinson disease, therapeutics | Phase 2/Phase 3 | Active not recruiting | 2021 |
| A Phase III randomized placebo controlled parallel group double blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension 2025-523481-24-00 — supranuclear palsy, progressive, safety, double-blind method, paralysis | Phase 3 | Recruiting | 2026 |
| Italian Translation and Validation of the GIDS PD Scale for Parkinson s Disease NCT07316751 — parkinson disease, multiple chronic conditions | N/A | Recruiting | 2025 |
| A Phase 2 Study and Open Label Extension of NEU 411 in Companion Diagnostic Positive Participants With Early Parkinson s Disease NCT06680830 — safety, parkinson disease, brain, leucine, small molecules | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map